ReviewCDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
Cited by (0)
Funding: This initiative was sponsored by Lilly through the provision of an unrestricted educational grant. Lilly has had no influence over the content other than a review of the paper for medical accuracy. The participants/authors received an honorarium for their participation in the round-table from BMJ.
Competing interests: MP: honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp & Dome. MT: advisory role at: Amgen, AstraZeneca, Celgene, Eisai, Genomic Health, Lilly, Neodynamics, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, SurgicEye, Tesaro, Teva. Speaker engagements and travel support: Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Eisai, Genomic Health, Medtronic, Myriad, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, Teva. Manuscript fees: Roche, Celgene. Trial funding: Genomic Health. RB: advisory role: Eli-Lilly, Novartis, Pfizer; Lecture honoraria: Eli-Lilly, Novartis, Pfizer; research support: Novartis; Travel support: Pfizer. TR: advisory role for: Lilly, Roche, Novartis, Pfizer, AstraZeneca; Travel support: Roche, Amgen. EdA: honoraria and advisory board: Roche/GNE; travel grants: Roche/GNE and GSK/Novartis; research grant: Roche/GNE. CZ: honoraria from Roche, Novartis, BMS, MSD, Imugene, Ariad, Pfizer, Merrimack, Merck KGaA, Fibrogen, AstraZeneca, Tesaro, Gilead, Servier, Shire.
Provenance and peer review: Commissioned; externally peer reviewed.